Full Press Release Details
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma.
ALXO
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Key Takeaway: ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)